AbCellera Biologics

AbCellera Biologics Inc. is a Canadian biotechnology company headquartered in Vancouver, British Columbia, that operates at the intersection of biology, engineering, and computation. Rather than functioning as a traditional pharmaceutical manufacturer, AbCellera positions itself as an antibody discovery and development platform company: it builds high-throughput technologies to screen vast numbers of immune cells, identify rare antibodies of interest, and then engineer and advance those molecules toward clinical use. Its proprietary discovery engine combines microfluidics, single-cell analysis, machine learning, and laboratory automation to compress the time required to find and characterize antibody candidates. The company became widely known through its role in the COVID-19 pandemic response. Working with Eli Lilly and Company, AbCellera identified and helped develop bamlanivimab, an antibody therapy that received emergency use authorization in the United States in late 2020 — one of the first antibody treatments authorized for COVID-19. That partnership brought AbCellera significant revenue and visibility, and it underpinned the company's decision to go public. AbCellera listed on the Nasdaq Global Select Market under the ticker ABCL in December 2020, raising substantial capital to expand its internal pipeline and manufacturing capabilities. The company has since invested in its own clinical-stage programs and in a large-scale manufacturing facility in Vancouver, while continuing to partner with large pharmaceutical companies on antibody discovery deals that typically include upfront payments, research funding, and downstream milestone and royalty economics. Commercially, AbCellera's model blends a technology-licensing and partnership business with an emerging proprietary drug pipeline. Its partners have included major biopharma players, and its internal programs span areas such as oncology, immunology, and infectious disease. The company's positioning emphasizes speed, scale, and data-driven discovery — presenting itself as a next-generation antibody foundry rather than a conventional drugmaker. AbCellera is a public company with no single controlling parent, headquartered in Vancouver, and it remains one of Canada's most prominent biotech platform companies. Its fortunes are tied to the broader antibody therapeutics market, the success of its partnered programs, and the progress of its own clinical pipeline.

AbCellera was founded in 2012 in Vancouver, British Columbia, by Carl Hansen, a physicist and professor who brought an engineering and computational perspective to antibody discovery. The company's founding premise was that the search for therapeutic antibodies could be dramatically accelerated by combining microfluidics, single-cell screening, and data science — allowing researchers to examine millions of immune cells and isolate the rare ones producing promising antibodies. Through the mid-2010s, AbCellera built out its discovery platform and entered partnerships with pharmaceutical companies seeking to outsource or accelerate antibody identification. These collaborations typically provided research funding and upfront payments, with the company retaining downstream economics through milestones and royalties. The company's breakout moment came in 2020 during the COVID-19 pandemic. AbCellera partnered with Eli Lilly and Company to identify antibodies from a recovered patient, leading to the development of bamlanivimab. The therapy received emergency use authorization from the U.S. Food and Drug Administration in November 2020, making it one of the first antibody treatments authorized for COVID-19. The partnership generated substantial revenue and raised AbCellera's profile globally. In December 2020, AbCellera completed an initial public offering on the Nasdaq Global Select Market under the ticker ABCL, raising capital to expand its platform, advance its internal pipeline, and invest in manufacturing. The company subsequently built a large-scale manufacturing facility in Vancouver and expanded its clinical-stage programs in areas including oncology and immunology. In the years after the pandemic, AbCellera shifted emphasis toward its proprietary pipeline and next-generation discovery capabilities, while continuing partnership-based discovery work with large biopharma companies. Its trajectory reflects the broader evolution of antibody discovery from bespoke laboratory work toward industrialized, data-driven platforms.

• 2020

  Partnered with Eli Lilly on bamlanivimab, which received U.S. emergency use authorization for COVID-19 in November 2020.

• 2020

  Completed initial public offering on Nasdaq under ticker ABCL in December 2020.

• 2012

  AbCellera founded in Vancouver, British Columbia by Carl Hansen.

A technology-driven antibody discovery and development platform company that partners with biopharma and advances its own pipeline, emphasizing speed and scale in antibody identification.

• Antibody discovery platform

  Proprietary technology combining microfluidics, single-cell analysis, machine learning, and automation to identify and engineer antibody candidates.

• Bamlanivimab

  COVID-19 antibody therapy co-developed with Eli Lilly, authorized for emergency use in the U.S. in 2020.

1. 1AbCellera official websiteabcellera.com
2. 2AbCellera launches stock offering for ABCL635bioxconomy.com